Table 1.
Lymphoma patient and noncancer control participant characteristics and demographics
| Characteristic | Lymphoma/Chemotherapy | Control | Total | P |
|---|---|---|---|---|
| (n = 248) | (n = 212) | (N = 460) | ||
| Age, y | .30b | |||
| Mean (SD) | 55.40 (14.70) | 53.96 (14.98) | 54.74 (14.83) | |
| Range | 21.00-83.00 | 18.00-84.00 | 18.00-84.00 | |
| Sex, No. (%) | .44a | |||
| Female | 93 (37.5) | 87 (41.0) | 180 (39.1) | |
| Male | 155 (62.5) | 125 (59.0) | 280 (60.9) | |
| Race, No. (%) | .44a | |||
| White | 232 (93.6) | 197 (92.9) | 429 (93.3) | |
| Black | 11 (4.4) | 7 (3.3) | 18 (3.9) | |
| Other | 5 (2.0) | 8 (3.8) | 13 (2.8) | |
| Ethnicity, No. (%) | .84a | |||
| Hispanic/Latino | 5 (2.0) | 6 (2.8) | 11 (2.4) | |
| Not Hispanic/Latino | 238 (96.0) | 201 (94.8) | 439 (95.4) | |
| Unknown | 5 (2.0) | 5 (2.4) | 10 (2.2) | |
| Education, No. (%) | .02a | |||
| < High school | 7 (2.8) | 1 (0.5) | 8 (1.7) | |
| High school/GED | 51 (20.6) | 27 (12.7) | 78 (17.0) | |
| Partial College and Higher | 189 (76.2) | 184 (86.8) | 373 (81.1) | |
| Unknown | 1 (0.4) | 0 (0.0) | 1 (0.2) | |
| Marital status, No. (%) | .48a | |||
| Married | 181 (73.0) | 149 (70.3) | 330 (71.7) | |
| Divorced | 16 (6.4) | 18 (8.5) | 34 (7.4) | |
| Long-term relationship | 18 (7.3) | 9 (4.2) | 27 (5.9) | |
| Separated | 3 (1.2) | 2 (0.9) | 5 (1.1) | |
| Single | 23 (9.3) | 23 (10.8) | 46 (10.0) | |
| Widowed | 7 (2.8) | 11 (5.1) | 18 (3.9) | |
| WRAT 4 Reading, mean (SD) | 62.86 (6.16) | 63.67 (4.83) | 63.24 (5.59) | .12b |
| Anxiety (STAI), mean (SD) | 34.95 (12.58) | 27.46 (9.21) | 31.48 (11.74) | <.001b |
| Depression item, mean (SD) | 0.64 (0.97) | 0.30 (0.61) | 0.48 (0.84) | <.001b |
| Lymphoma type, No. (%) | ||||
| Hodgkin | 51 (20.6) | — | — | |
| Non-Hodgkin | 186 (75.0) | — | — | |
| Unknown | 11 (4.4) | — | — | |
| Lymphoma subtype, No. (%) | ||||
| NHL subtypes | ||||
| DLBCL | 98 (39.5) | — | — | |
| Follicular | 41 (16.5) | — | — | |
| Other B cell | 29 (11.7) | |||
| T cell | 8 (3.2) | — | — | |
| HL subtype | — | — | ||
| Classical | 45 (18) | — | — | |
| Lymphocyte predominant | 3 (1.2) | — | — | |
| Unknown subtype | 24 (9.7) | — | — | |
| Lymphoma regimen, No. (%) | ||||
| ABVD | 42 (16.9) | — | — | |
| BR | 35 (14.1) | — | — | |
| Other | 26 (10.5) | — | — | |
| R-CHOP | 116 (46.8) | — | — | |
| Unknown | 29 (11.7) | — | — |
a
Two-sided Pearson χ2 test. ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; BR = bendamustine and rituximab; DLBCL = diffuse large B-cell lymphoma; GED = general equivalency diploma; NHL = non-Hodgkin lymphoma; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; STAI = Spielberger Trait Anxiety Inventory; WRAT-4 = Wide Range Achievement Test, 4th edition; — = not applicable.
b
Welch t test. All tests were 2-sided.